Tonix Pharmaceuticals Holding Corp (TNXP)
0.18
0.00 (0.00%)
USD |
NASDAQ |
May 02, 13:42
Tonix Pharmaceuticals Research and Development Expense (Quarterly): 17.12M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 17.12M |
| September 30, 2023 | 21.05M |
| June 30, 2023 | 21.98M |
| March 31, 2023 | 26.51M |
| December 31, 2022 | 24.67M |
| September 30, 2022 | 22.20M |
| June 30, 2022 | 16.58M |
| March 31, 2022 | 18.42M |
| December 31, 2021 | 22.30M |
| September 30, 2021 | 13.08M |
| June 30, 2021 | 18.13M |
| March 31, 2021 | 15.33M |
| December 31, 2020 | 12.10M |
| September 30, 2020 | 8.813M |
| June 30, 2020 | 10.57M |
| March 31, 2020 | 4.676M |
| December 31, 2019 | 5.69M |
| September 30, 2019 | 5.052M |
| June 30, 2019 | 3.554M |
| March 31, 2019 | 3.896M |
| December 31, 2018 | 5.057M |
| September 30, 2018 | 3.264M |
| June 30, 2018 | 4.067M |
| March 31, 2018 | 5.17M |
| December 31, 2017 | 3.634M |
| Date | Value |
|---|---|
| September 30, 2017 | 3.908M |
| June 30, 2017 | 2.806M |
| March 31, 2017 | 2.994M |
| December 31, 2016 | 4.88M |
| September 30, 2016 | 5.466M |
| June 30, 2016 | 7.516M |
| March 31, 2016 | 10.67M |
| December 31, 2015 | 9.49M |
| September 30, 2015 | 10.31M |
| June 30, 2015 | 8.871M |
| March 31, 2015 | 6.829M |
| December 31, 2014 | 5.775M |
| September 30, 2014 | 5.217M |
| June 30, 2014 | 4.075M |
| March 31, 2014 | 3.55M |
| December 31, 2013 | 1.328M |
| September 30, 2013 | 1.637M |
| June 30, 2013 | 0.944M |
| March 31, 2013 | 0.741M |
| December 31, 2012 | 0.7004M |
| September 30, 2012 | 0.6581M |
| June 30, 2012 | 0.8278M |
| March 31, 2012 | 0.3976M |
| December 31, 2011 | 0.5237M |
| September 30, 2011 | 0.492M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
3.554M
Minimum
Jun 2019
26.51M
Maximum
Mar 2023
15.15M
Average
16.58M
Median
Jun 2022
Research and Development Expense (Quarterly) Benchmarks
| PetVivo Holdings Inc | 0.2311M |
| Acurx Pharmaceuticals Inc | 1.943M |
| ACADIA Pharmaceuticals Inc | 66.74M |
| Kezar Life Sciences Inc | 22.64M |
| Allakos Inc | 53.80M |